- Home
- PROK vs SOL Comparison
PROK vs SOL Comparison
Compare PROK & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- SOL
- Stock Information
- Founded
- PROK 2015
- SOL 2005
- Country
- PROK United States
- SOL United States
- Employees
- PROK N/A
- SOL N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- SOL Semiconductors
- Sector
- PROK Health Care
- SOL Technology
- Exchange
- PROK Nasdaq
- SOL Nasdaq
- Market Cap
- PROK 85.5M
- SOL 94.9M
- IPO Year
- PROK N/A
- SOL 2008
- Fundamental
- Price
- PROK $0.58
- SOL $1.90
- Analyst Decision
- PROK Hold
- SOL Strong Buy
- Analyst Count
- PROK 3
- SOL 2
- Target Price
- PROK $3.50
- SOL $4.50
- AVG Volume (30 Days)
- PROK 1.6M
- SOL 325.5K
- Earning Date
- PROK 08-08-2025
- SOL 08-19-2025
- Dividend Yield
- PROK N/A
- SOL N/A
- EPS Growth
- PROK N/A
- SOL N/A
- EPS
- PROK N/A
- SOL N/A
- Revenue
- PROK $306,000.00
- SOL $85,621,000.00
- Revenue This Year
- PROK $54.34
- SOL N/A
- Revenue Next Year
- PROK N/A
- SOL $45.37
- P/E Ratio
- PROK N/A
- SOL N/A
- Revenue Growth
- PROK N/A
- SOL N/A
- 52 Week Low
- PROK $0.46
- SOL $1.04
- 52 Week High
- PROK $2.59
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- PROK 39.22
- SOL 61.66
- Support Level
- PROK $0.54
- SOL $1.84
- Resistance Level
- PROK $0.90
- SOL $1.91
- Average True Range (ATR)
- PROK 0.13
- SOL 0.05
- MACD
- PROK -0.03
- SOL -0.00
- Stochastic Oscillator
- PROK 8.06
- SOL 93.18
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.